Can a patient with glaucoma take Flonase (fluticasone propionate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can a Patient with Glaucoma Take Flonase?

Yes, patients with glaucoma can safely use Flonase (fluticasone propionate nasal spray), as intranasal corticosteroids at recommended doses do not increase the risk of glaucoma or elevated intraocular pressure. 1

Evidence Supporting Safety in Glaucoma Patients

The most definitive evidence comes from prospective studies showing that intranasal corticosteroids, including fluticasone propionate, do not pose a risk for glaucoma development:

  • Patients receiving standard doses of intranasal corticosteroids are not at increased risk for the development of glaucoma. 1

  • Long-term use of intranasal steroids has not been shown to increase the risk of elevated intraocular pressure or any other ocular symptoms. 1

  • Studies of intranasal corticosteroids in prospective trials of 24 weeks have not demonstrated the development of lenticular changes consistent with posterior subcapsular cataracts. 1

Critical Distinction: Route of Administration Matters

The key to understanding this safety profile is recognizing that the route of corticosteroid administration dramatically affects glaucoma risk:

  • Topical ocular corticosteroids (eye drops) pose a real danger to patients with open-angle glaucoma, as they can cause vision loss that is gradual, insidious, and irreversible. 2

  • Chronic use of corticosteroids, especially as eye drops, can cause elevated intraocular pressure through increased aqueous outflow resistance due to accumulation of extracellular matrix material in the trabecular meshwork. 3

  • In contrast, intranasal corticosteroids have minimal systemic absorption and do not achieve the ocular tissue concentrations necessary to affect intraocular pressure. 1, 4

Rare Instances and Individual Variability

While the evidence strongly supports safety, the FDA label acknowledges extremely rare occurrences:

  • Rare instances of glaucoma and increased intraocular pressure have been reported following intranasal application of corticosteroids, including fluticasone propionate. 5

  • Individual patient variability may allow for the development of ocular effects from intranasal corticosteroids, especially in older patients. 1

  • Corticosteroid responsiveness varies between individuals, with the most important risk factor being personal or family history of primary open-angle glaucoma. 6

Monitoring Recommendations

For patients with pre-existing glaucoma using intranasal corticosteroids long-term, consider the following approach:

  • Patients on long-term topical nasal steroids should consult their physicians to determine if regular ophthalmic monitoring is appropriate. 1

  • This is a discretionary recommendation based on theoretical risk rather than demonstrated harm in clinical trials. 1

  • No routine monitoring is required for short-term use (less than 12 weeks). 4

Common Pitfall to Avoid

Do not confuse the contraindication for topical ocular corticosteroids with the safety profile of intranasal corticosteroids. The package insert warning about glaucoma that appears on many medications can be misleading when it comes to intranasal steroids. 2 The chronic use of corticosteroid eye drops is what poses genuine risk to glaucoma patients, not nasal sprays. 2

Proper Administration to Maximize Safety

To minimize any theoretical systemic absorption:

  • Direct the spray away from the nasal septum using the contralateral hand technique. 4

  • Use the lowest effective dose for symptom control. 4

  • Patients should be instructed on proper administration technique to optimize local delivery and minimize systemic effects. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Intranasal Steroid Recommendations for Allergic Rhinitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

[Corticosteroids and glaucoma].

Revue medicale suisse, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.